Griffon Pharmaceuticals International SA est une AG suisse basée à Epalinges, VD. Son activité enregistrée relève de Recherche et développement dans l'industrie pharmaceutique.
Synthèse du registre générée à partir des faits FOSC.
la société a pour but: la recherche, le développement, la production et le commerce (achat, vente, import, export, représentation) de produits issus de la biotechnologie, de produits pharmaceutiques et de dispositifs médicaux, d'acheter, utiliser, vendre ou échanger des brevets, procédés de fabrication et marques de fabrique et la concession ou l'utilisation de licences y relatives, ainsi que la prestation de tous services dans ces domaines notamment la mise au point de thérapie et diagnostique (pour but complet cf. statuts).
Route de la Corniche 3, c/o Biopôle SA, Bâtiment SE-A, 1066 Epalinges
1066, Epalinges, VD
Récupérez les données de vos fournisseurs connectés et fusionnez-les avec le registre.
Le pouls du registre est une fonctionnalité Pro
Full List of Biotech Companies in Switzerland (2026)
pharmchoices.com
Griffon Pharmaceuticals International • Biopôle • Switzerland
biopole.ch
Griffon Pharmaceuticals International SA, Epalinges | OnlineInfo.ch Firmeninformation
onlineinfo.ch
Marc Cluzel: Postes, Relations & Réseau - Zonebourse
zonebourse.com
Pegylated bioactive peptides and uses thereof (US Patent 10918730)
exa.ai
Attending companies 2025 - Swiss Biotech Day
swissbiotechday.ch
NOTICE: CORRECTION TO NOTICE OF INTENT ISSUED JAN. 25, 2021 - VA Offer of Exclusive Patent License to Griffon Pharmaceuticals Inc. BY THE: Department of Veterans Affairs, Office of Research and Development (VA) ON: March 25, 2021 SUMMARY: As stated in the original notice of January 25, 2021, the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to Griffon Pharmaceuticals, an exclusive license to U.S. Patent Application No. 16/611,147 and PCT/US2018/031261, associated with VA Invention Disclosure number 2016-145 titled, “Methods and Composition for Treating Liver Disease”. However, Griffon Pharmaceuticals’ corporate entity and address for this license agreement have changed to the following: Griffon Pharmaceuticals International SA, Route de la Corniche 3, Bâtiment SE-A, 1066 Épalinges, Switzerland. TECH NAME: “Methods and Composition for Treating Liver Disease” ACTION: CORRECTION TO NOTICE OF INTENT DATES: Comments must be received on or before April 14, 2021. ADDRESS: Send comments to Mr. Stefan Susta, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (937) 409-7993 (this is not a toll-free number), Email: stefan.susta@va.gov FOR FURTHER INFORMATION CONTACT: Send comments to Mr. Stefan Susta, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (937) 409-7993 (this is not a toll-free number), Email: stefan.susta@va.gov
federallabs.org